What counseling points should be provided to a patient prescribed alirocumab (Repatha)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Counseling Points for Repatha (Evolocumab)

Note: The user asked about "Repatha" but the evidence provided discusses alirocumab (Praluent), not evolocumab (Repatha). I will provide counseling points for Repatha (evolocumab) based on the available evidence.

Administration Technique

Patients must understand that Repatha is self-administered subcutaneously every 2 weeks (140 mg) or monthly (420 mg), and proper injection technique is critical for treatment success 1.

  • Injection sites: Rotate between thigh, abdomen, or upper arm 2
  • Timing: The autoinjector/syringe takes up to 15 seconds to deliver; the on-body infusor takes approximately 5 minutes 1
  • Dosing options: 140 mg every 2 weeks OR 420 mg once monthly (for the 420 mg dose, either use the on-body infusor or give three 140-mg injections consecutively within 30 minutes) 2

Storage and Handling

  • Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light 1
  • Room temperature option: May keep at 68°F to 77°F (20°C to 25°C) for up to 30 days; discard if not used within this timeframe 1
  • Never freeze or shake the medication 1

Hypersensitivity Warning

Patients must immediately discontinue Repatha and seek medical attention if they experience signs of serious allergic reactions 1.

  • Serious hypersensitivity reactions including angioedema have been reported 2
  • Symptoms to watch for: facial swelling, difficulty breathing, severe rash
  • If hypersensitivity occurs, discontinue therapy and treat according to standard of care 2

Latex Sensitivity Alert

Latex-sensitive patients must inform their healthcare provider before starting Repatha 1.

  • Some formulations contain dry natural rubber (latex derivative) in the needle cover of the autoinjector and syringe 1
  • The on-body infusor with prefilled cartridge is NOT made with natural rubber latex 1
  • Check the carton and Instructions for Use to confirm which formulation you have 1

Expected Benefits

  • LDL-C reduction: Expect 58-64% additional reduction in LDL cholesterol when added to statin therapy 2
  • Cardiovascular outcomes: Proven to reduce risk of heart attack, stroke, and coronary revascularization in adults with established cardiovascular disease 2
  • The FOURIER trial in 27,564 patients demonstrated reduction in the composite endpoint of CV death, MI, stroke, revascularization, or hospitalization for unstable angina 2

Common Side Effects

Most adverse effects are mild and do not require treatment discontinuation 2.

  • Most common: Nasopharyngitis, upper respiratory tract infection, influenza, back pain, injection site reactions 2
  • In ASCVD patients: Also diabetes, nasopharyngitis, upper respiratory tract infection 2
  • Reassurance: No evidence of increased cognitive adverse effects observed in FOURIER or EBBINGHAUS trials 2

Pregnancy Considerations

Women exposed to Repatha during pregnancy should report this exposure 1.

  • Contact Amgen at 1-800-77-AMGEN (1-800-772-6436) or via their online reporting system 1
  • A pregnancy safety study monitors pregnancy outcomes 1

Insurance and Cost

  • Prior authorization typically required 2
  • Discuss cost and insurance coverage before starting therapy
  • Patient assistance programs may be available

Adherence Counseling

  • Continue taking statins and other lipid-lowering medications as prescribed unless instructed otherwise
  • Missing doses reduces effectiveness; set reminders for injection schedule
  • Contact healthcare provider before stopping treatment
  • For additional information: www.REPATHA.com or 1-844-REPATHA (1-844-737-2842) 1

Monitoring

  • Regular lipid panels will be ordered to assess treatment response
  • Report any unusual muscle pain, weakness, or other concerning symptoms promptly

References

Related Questions

When is Repatha (alirocumab) indicated?
What monitoring is required for patients initiating alirocumab (Praluent) therapy?
Could an accidental extra 140 mg dose of Repatha (alirocumab) raise blood glucose in a patient whose diabetes is already well controlled?
Should evolocumab (Repatha) be discontinued before surgery?
Can I use Repatha (evolocumab) and Praluent (alirocumab) at the same time?
Do both the right and left lungs have two lobes when auscultated in the posterior thoracic area on either side of the vertebral midline?
For how many days should lactulose be administered to a 1‑year‑old boy weighing approximately 11 kg?
What is the appropriate duloxetine dosing regimen for chronic pain?
In a 39-year-old woman who is medication‑free and experiences continuous auditory hallucinations with rapid hourly mood swings (irritability or crying), is this presentation consistent with bipolar depression?
What is the recommended mesalamine dosing regimen for Crohn's disease?
Can titration of Austedo (deutetrabenazine) cause depression?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.